How has newly diagnosed #Type2Diabetes evolved? A 180k+ cohort over 15 years: older, multimorbid, #MASLD surge, yet better glycaemic management. Uptake of #SGLT2i and #GLP1RA + >5-fold drop in sulfonylureas—a cardiorenal/weight paradigm shift link.springer.com/article/10.1... 🔓
October 27, 2026 at 12:03 PM
How has newly diagnosed #Type2Diabetes evolved? A 180k+ cohort over 15 years: older, multimorbid, #MASLD surge, yet better glycaemic management. Uptake of #SGLT2i and #GLP1RA + >5-fold drop in sulfonylureas—a cardiorenal/weight paradigm shift link.springer.com/article/10.1... 🔓
Casi la mitad de los que usan un agonista del receptor GLP-1 reducen su consumo de alcohol, siendo más propensos a reducirlo los que tienen un consumo potencialmente insano #alcohol #GLP1RA jamanetwork.com/journals/jam...
Patient-Reported Changes in Alcohol Use Following GLP-1 RA Initiation
This survey study with a nationally representative sample evaluates whether individuals who initiate glucagon-like peptide-1 receptor agonists (GLP-1 RAs) report reducing alcohol consumption after sta...
jamanetwork.com
October 20, 2026 at 12:27 PM
Casi la mitad de los que usan un agonista del receptor GLP-1 reducen su consumo de alcohol, siendo más propensos a reducirlo los que tienen un consumo potencialmente insano #alcohol #GLP1RA jamanetwork.com/journals/jam...
En adultos c/HTA resistente y sobrepeso u obesidad, agonistas rec GLP-1 se asocian c/menos riesgos CV y renales que antagonistas rec mineralocorticoides a pesar de reducciones similares de la presión arterial #GLP1RA #MRA #ResistantHypertension www.thelancet.com/journals/ecl...
Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obes...
In our retrospective study, among adults with resistant hypertension and overweight
or obesity, GLP-1RA was associated with lower cardiovascular and kidney risk compared
with MRAs despite smaller bloo...
www.thelancet.com
October 19, 2026 at 2:13 PM
En adultos c/HTA resistente y sobrepeso u obesidad, agonistas rec GLP-1 se asocian c/menos riesgos CV y renales que antagonistas rec mineralocorticoides a pesar de reducciones similares de la presión arterial #GLP1RA #MRA #ResistantHypertension www.thelancet.com/journals/ecl...
Missed this: the REMODEL study of the mechanistic insight into GLP1RA action in kidneys now in @naturemedicine.bsky.social
www.nature.com/articles/s41...
#OpenAccess
www.nature.com/articles/s41...
#OpenAccess
Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial - Nature Medicine
A randomized trial in individuals with type 2 diabetes probed the kidney-protective mechanisms of semaglutide using a range of techniques, including histology, multiparametric MRI and transcriptomics.
www.nature.com
October 16, 2026 at 12:30 AM
Missed this: the REMODEL study of the mechanistic insight into GLP1RA action in kidneys now in @naturemedicine.bsky.social
www.nature.com/articles/s41...
#OpenAccess
www.nature.com/articles/s41...
#OpenAccess
Deficiencias nutricionales son un riesgo significativo no reconocido en pacientes pediátricos que reciben terapia con agonistas del receptor del GLP-1 #GLP1RA #nutritional #deficiency #pediatric journals.sagepub.com/doi/10.1177/...
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
September 29, 2026 at 7:18 AM
Deficiencias nutricionales son un riesgo significativo no reconocido en pacientes pediátricos que reciben terapia con agonistas del receptor del GLP-1 #GLP1RA #nutritional #deficiency #pediatric journals.sagepub.com/doi/10.1177/...
No hay evidencia de relación entre GLP-1RA y suicidalidad o daño psiquiátrico mayor, persiste incertidumbre en subgrupos psiquiátricamente vulnerables #GLP1RA #suicidalideation #depression #drugsafety www.mdpi.com/4006934
www.mdpi.com
September 14, 2026 at 10:55 AM
No hay evidencia de relación entre GLP-1RA y suicidalidad o daño psiquiátrico mayor, persiste incertidumbre en subgrupos psiquiátricamente vulnerables #GLP1RA #suicidalideation #depression #drugsafety www.mdpi.com/4006934
Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care data - The Lancet Primary Care www.thelancet.com/journals/lan...
Supports benefits of GLP1RA + SGLT2i & useful discussion in letters.
Supports benefits of GLP1RA + SGLT2i & useful discussion in letters.
Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care data
These real-world data suggest that the kidney-protective benefits of GLP-1 receptor
agonists observed in randomised trials of individuals with type 2 diabetes might also
extend to individuals already ...
www.thelancet.com
September 10, 2026 at 10:36 AM
Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care data - The Lancet Primary Care www.thelancet.com/journals/lan...
Supports benefits of GLP1RA + SGLT2i & useful discussion in letters.
Supports benefits of GLP1RA + SGLT2i & useful discussion in letters.
💉 GLP-1 receptor agonists may offer benefits in hemodialysis.
In a cohort of 4,984 patients, their use was associated with 9% fewer hospitalizations and 17% lower mortality.
Observational findings that require confirmation.
#Nephrology #GLP1RA
🔗 journals.lww.com/cjasn/pdf/10...
In a cohort of 4,984 patients, their use was associated with 9% fewer hospitalizations and 17% lower mortality.
Observational findings that require confirmation.
#Nephrology #GLP1RA
🔗 journals.lww.com/cjasn/pdf/10...
September 8, 2026 at 3:22 PM
💉 GLP-1 receptor agonists may offer benefits in hemodialysis.
In a cohort of 4,984 patients, their use was associated with 9% fewer hospitalizations and 17% lower mortality.
Observational findings that require confirmation.
#Nephrology #GLP1RA
🔗 journals.lww.com/cjasn/pdf/10...
In a cohort of 4,984 patients, their use was associated with 9% fewer hospitalizations and 17% lower mortality.
Observational findings that require confirmation.
#Nephrology #GLP1RA
🔗 journals.lww.com/cjasn/pdf/10...
GLP1RA use in adults with #HidradenitisSuppurativa (the skin abscess thing I have) was associated with lower mortality, major cardiovascular events, cellulitis, and sepsis over 1- and 2-year follow-up in a large matched cohort study
Score!
Score!
September 4, 2026 at 12:37 PM
GLP1RA use in adults with #HidradenitisSuppurativa (the skin abscess thing I have) was associated with lower mortality, major cardiovascular events, cellulitis, and sepsis over 1- and 2-year follow-up in a large matched cohort study
Score!
Score!
Clinical measurement of #GLP1Ra #gastrointestinal side effects can involve invasive procedures — could there be a better way? With help from Promethion #Metabolic Cages, scientists developed a noninvasive measure of oral–cecal transit time based on #13C-labeled mannitol #metabolism.
buff.ly/5kEFup9
buff.ly/5kEFup9
A noninvasive 13C-mannitol breath test to monitor semaglutide treatment-induced delayed oral-cecal transit in mice | American Journal of Physiology-Endocrinology and Metabolism | American Physiological Society
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, are highly effective treatments for obesity and type 2 diabetes but are often associated with gastrointestinal side effects…
journals.physiology.org
September 1, 2026 at 7:01 PM
Clinical measurement of #GLP1Ra #gastrointestinal side effects can involve invasive procedures — could there be a better way? With help from Promethion #Metabolic Cages, scientists developed a noninvasive measure of oral–cecal transit time based on #13C-labeled mannitol #metabolism.
buff.ly/5kEFup9
buff.ly/5kEFup9
Rates of simple incision and drainage, complicated incision and drainage & various wide local excision types for hidradenitis suppurativa treatment are lower in patients who received #GLP1RA.
https://www.dermatologyadvisor.com/news/glp-1-ra-use-associated-fewer-surgeries-hidradenitis-suppurativa/
https://www.dermatologyadvisor.com/news/glp-1-ra-use-associated-fewer-surgeries-hidradenitis-suppurativa/
GLP-1 RA Use Is Associated With Fewer Surgeries for Hidradenitis Suppurativa
The use of GLP-1 RAs was associated with lower rates of surgical procedures performed among patients with HS when compared with control patients.
www.dermatologyadvisor.com
August 25, 2026 at 4:44 PM
Rates of simple incision and drainage, complicated incision and drainage & various wide local excision types for hidradenitis suppurativa treatment are lower in patients who received #GLP1RA.
https://www.dermatologyadvisor.com/news/glp-1-ra-use-associated-fewer-surgeries-hidradenitis-suppurativa/
https://www.dermatologyadvisor.com/news/glp-1-ra-use-associated-fewer-surgeries-hidradenitis-suppurativa/
⭐️The PHuture is bright! ⭐️
Dr. Ahmed Chaaban, an Internal Medicine resident at the University of Buffalo, discusses the effect of GLP1RA vs SGLT2I in PH patients. 👏
Dr. Ahmed Chaaban, an Internal Medicine resident at the University of Buffalo, discusses the effect of GLP1RA vs SGLT2I in PH patients. 👏
May 17, 2026 at 3:15 PM
⭐️The PHuture is bright! ⭐️
Dr. Ahmed Chaaban, an Internal Medicine resident at the University of Buffalo, discusses the effect of GLP1RA vs SGLT2I in PH patients. 👏
Dr. Ahmed Chaaban, an Internal Medicine resident at the University of Buffalo, discusses the effect of GLP1RA vs SGLT2I in PH patients. 👏
The issues around GLP1RA supply are causing lot of work for primary care and obviously impacting many patients.
I've heard a suggestion to stop off licence prescribing.
Is this feasible, and would prescribers tolerate such an imposition
I've heard a suggestion to stop off licence prescribing.
Is this feasible, and would prescribers tolerate such an imposition
November 27, 2024 at 9:08 PM
The issues around GLP1RA supply are causing lot of work for primary care and obviously impacting many patients.
I've heard a suggestion to stop off licence prescribing.
Is this feasible, and would prescribers tolerate such an imposition
I've heard a suggestion to stop off licence prescribing.
Is this feasible, and would prescribers tolerate such an imposition
💬 Editor's Note: Oral #GLP1RA therapies offer new options for cardiovascular risk reduction, supporting shared decision-making for patients and clinicians as the landscape evolves beyond injectable agents.
ja.ma/4dHrVRK
ja.ma/4dHrVRK
March 25, 2026 at 4:00 PM
💬 Editor's Note: Oral #GLP1RA therapies offer new options for cardiovascular risk reduction, supporting shared decision-making for patients and clinicians as the landscape evolves beyond injectable agents.
ja.ma/4dHrVRK
ja.ma/4dHrVRK
From @dgsomucla.bsky.social and @smidtheart.bsky.social:
High-dose #GLP1RA therapy is associated with a reduced risk for #HepaticEncephalopathy, supporting its use for patients without #LiverCancer.
High-dose #GLP1RA therapy is associated with a reduced risk for #HepaticEncephalopathy, supporting its use for patients without #LiverCancer.
Do GLP-1 RAs Reduce Hepatic Encephalopathy Risk in Cirrhosis?
High-dose GLP-1 RA use is associated with a significantly lower risk for hepatic encephalopathy and mortality in cirrhosis.
www.gastroenterologyadvisor.com
June 24, 2026 at 7:20 PM
From @dgsomucla.bsky.social and @smidtheart.bsky.social:
High-dose #GLP1RA therapy is associated with a reduced risk for #HepaticEncephalopathy, supporting its use for patients without #LiverCancer.
High-dose #GLP1RA therapy is associated with a reduced risk for #HepaticEncephalopathy, supporting its use for patients without #LiverCancer.
#GLP1RA use is not associated with significant differences in #esophageal motility disorders among those with #T2D undergoing #HighResolutionManometry.
GLP-1 RA Use Does Not Affect Esophageal Function in Type 2 Diabetes
GLP-1 RA use is not associated with significant unfavorable effects on esophageal function in those with T2D undergoing HRM.
www.gastroenterologyadvisor.com
June 18, 2026 at 9:06 PM
#GLP1RA use is not associated with significant differences in #esophageal motility disorders among those with #T2D undergoing #HighResolutionManometry.
#GLP1RA therapy is associated with significantly lower rates of liver-related complications among those with #MASLD and #T2D.
GLP-1 RAs Reduce Risk for Hepatic Complications in MASLD and T2D
GLP-1 RA use is associated with a 38% to 42% lower risk for hepatic complications, including cirrhosis, among those with MASLD and T2D.
www.gastroenterologyadvisor.com
June 18, 2026 at 4:48 PM
Use of glucagon-like peptide-1 receptor agonists (#GLP1RA) in adults with type 2 #diabetes was associated with an increased risk of new chronic cough compared with other second-line diabetes medications.
bit.ly/4koi9We
bit.ly/4koi9We
February 19, 2026 at 1:00 PM
Use of glucagon-like peptide-1 receptor agonists (#GLP1RA) in adults with type 2 #diabetes was associated with an increased risk of new chronic cough compared with other second-line diabetes medications.
bit.ly/4koi9We
bit.ly/4koi9We
Use of glucagon-like peptide-1 receptor agonists (#GLP1RA) in adults with type 2 #diabetes was associated with an increased risk of new chronic cough compared with other second-line diabetes medications.
ja.ma/3LZtgrs
ja.ma/3LZtgrs
December 3, 2025 at 3:00 PM
Use of glucagon-like peptide-1 receptor agonists (#GLP1RA) in adults with type 2 #diabetes was associated with an increased risk of new chronic cough compared with other second-line diabetes medications.
ja.ma/3LZtgrs
ja.ma/3LZtgrs
Use of glucagon-like peptide-1 receptor agonists (#GLP1RA) in adults with type 2 #diabetes was associated with an increased risk of new chronic cough compared with other second-line diabetes medications.
ja.ma/4rnkMKU
ja.ma/4rnkMKU
November 30, 2025 at 3:00 PM
Use of glucagon-like peptide-1 receptor agonists (#GLP1RA) in adults with type 2 #diabetes was associated with an increased risk of new chronic cough compared with other second-line diabetes medications.
ja.ma/4rnkMKU
ja.ma/4rnkMKU
Use of glucagon-like peptide-1 receptor agonists (#GLP1RA) in adults with type 2 #diabetes was associated with an increased risk of new chronic cough compared with other second-line diabetes medications.
ja.ma/3M2FsYm
ja.ma/3M2FsYm
November 28, 2025 at 3:00 PM
Use of glucagon-like peptide-1 receptor agonists (#GLP1RA) in adults with type 2 #diabetes was associated with an increased risk of new chronic cough compared with other second-line diabetes medications.
ja.ma/3M2FsYm
ja.ma/3M2FsYm
Use of glucagon-like peptide-1 receptor agonists (#GLP1RA) in adults with type 2 #diabetes was associated with an increased risk of new chronic cough compared with other second-line diabetes medications.
ja.ma/3XfGfHV
ja.ma/3XfGfHV
November 26, 2025 at 4:30 PM
Use of glucagon-like peptide-1 receptor agonists (#GLP1RA) in adults with type 2 #diabetes was associated with an increased risk of new chronic cough compared with other second-line diabetes medications.
ja.ma/3XfGfHV
ja.ma/3XfGfHV
Of course I have receipts because of my autism 😂 but this graphic from this paper: pubmed.ncbi.nlm.nih.gov/39768911/
GLP1/GIP absolutely mess with inflammatory markers.
Also separately has been shown that GLP1RA attenuates toll like receptor(TRL) driven inflammation in the gut.
GLP1/GIP absolutely mess with inflammatory markers.
Also separately has been shown that GLP1RA attenuates toll like receptor(TRL) driven inflammation in the gut.
December 18, 2025 at 3:16 PM
Of course I have receipts because of my autism 😂 but this graphic from this paper: pubmed.ncbi.nlm.nih.gov/39768911/
GLP1/GIP absolutely mess with inflammatory markers.
Also separately has been shown that GLP1RA attenuates toll like receptor(TRL) driven inflammation in the gut.
GLP1/GIP absolutely mess with inflammatory markers.
Also separately has been shown that GLP1RA attenuates toll like receptor(TRL) driven inflammation in the gut.
Could GLP-1 Receptor Agonists Help Prevent Infections in People with Diabetes? A Nationwide Study Says Yes—At Least for the Lungs and Feet #ActAgainstAmputation #DiabeticFoot #GLP1RA diabeticfootonline.c...
April 23, 2026 at 4:56 PM
Could GLP-1 Receptor Agonists Help Prevent Infections in People with Diabetes? A Nationwide Study Says Yes—At Least for the Lungs and Feet #ActAgainstAmputation #DiabeticFoot #GLP1RA diabeticfootonline.c...